CLSI M24

Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes, 3rd Edition

This standard provides protocols and related quality control parameters for antimicrobial susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes.

Supplemental tables for M24 are published in CLSI document M24S.

This edition of the document was corrected in October 2019 and April 2020. Read the correction notices by accessing the link above, and learn more about our corrections process here.

This document is available in electronic format only.

More Details

Member price:

List Price:

Details

Chairholder: Gail L. Woods, MD

Date of Publication: November 28, 2018

Order Code PDF: CLSI M24Ed3E
ISBN Number: 978-1-68440-026-3

Order Code Print: print not available

Edition: Third

Pages: 110

CLSI M24 Additional Details

If interested in ordering larger quantities of this document in print, please contact us here.

A standard for global application developed through the Clinical and Laboratory Standards Institute consensus process.

CLSI M24 Abstract

Clinical and Laboratory Standards Institute standard M24—Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes includes susceptibility testing procedures for Mycobacterium tuberculosis complex (MTBC), clinically significant slowly and rapidly growing mycobacterial species, Nocardia spp., and other aerobic actinomycetes. Also included in this standard are recommendations for selecting agents for first-line and second-line drug testing, organism group–specific methodologies, reporting recommendations, and organism quality control criteria. Recommendations regarding agent selection for testing mycobacteria are based primarily on published guidelines. For testing MTBC, M24 recognizes agar proportion as the reference methodology on which all other methodologies are based. In addition, this standard includes recommendations for using commercial broth susceptibility methods with shorter incubation times, which are now in widespread use for MTBC susceptibility testing, and information on molecular methods for detecting drug resistance and their integration with culture-based methods.